Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Acetaminophen and pregnancy

This article was originally published in The Tan Sheet

Executive Summary

N-acetylcysteine (NAC), an antidote for acetaminophen toxicity, "should be initiated early after acetaminophen overdosage in pregnancy to prevent harm to both the mother and fetus," a study published in the November Southern Medical Journal states. "Limited data based mainly on case reports suggests that NAC may be safely administered during pregnancy and should be initiated early" after overdose, Jason Wilkes, MD, University of South Alabama College of Medicine, et al., conclude. Authors reviewed literature published from 1966 to present that was obtained through the OvidMEDLINE database. A study of pregnant women who overdosed on acetaminophen that was conducted at the Rocky Mountain Poison & Drug Center found that delivery of "normal infants" was more likely among women who had been administered NAC within 10 hours of overdose than in women treated within 16-24 hours...

You may also be interested in...

European SEAC Opinion Unchanged: Microplastics Must Be Out Of All Cosmetics Within Six Years

The final opinion of ECHA’s Socio-Economic Analysis Committee, published on 1 March, is largely unchanged from its July 2020 draft opinion with regard to microplastic in cosmetic products. That means industry may have to convince EU member state authorities that the restriction proposal has a serious proportionality problem.

QUOTED. 2 March 2021. Michael Coyle.

Representatives from cardiac monitoring device manufacturers and professional societies are working together to persuade Medicare carrier Novitas to reconsider its payment rates for extended cardiac monitoring. See what Michael Coyle, iRhythm’s CEO, said about it here.

Drug Manufacturers Beg US FDA To Inspect Facilities, But Still Find Difficulties

As agency implements testing contract for its staff, sponsors are drawing up protocols to ensure inspector safety and forwarding them to FDA, but still can’t trigger an inspection.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts